Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease

Trial Profile

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Azeliragon (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms STEADFAST-Extension
  • Sponsors vTv Therapeutics LLC
  • Most Recent Events

    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 17 Nov 2016 Planned End Date changed from 1 Jun 2019 to 1 Nov 2020.
    • 17 Nov 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top